DRREDDY
Built its reputation as an aggressive patent challenger rather than a quiet generic maker, becoming the first Indian company to launch a generic version of a major US branded drug (fluoxetine, Eli Lilly's Prozac) in 2001. Beyond finished generics it is also one of the world's larger suppliers of active ingredients to other drugmakers.
Pharmaceuticals - Generics & APIs
Generic and branded generic formulations, active pharmaceutical ingredients sold to other drugmakers, biosimilars and a smaller proprietary products pipeline.
Patients through pharmacies mainly in the US, India, Russia and Europe, plus other pharmaceutical companies that buy its bulk active ingredients rather than its finished drugs.
Combines finished-generic sales with a sizeable API business supplying other manufacturers. Profit swings with US generic pricing and patent-challenge outcomes, currency movements on its large export book, and how well newer biosimilars offset pressure on the older generics portfolio.
The options-implied volatility comes from the live chain, which is available during and around market hours (9:15-3:30 IST, Mon-Fri). The stock has realized 19.6% volatility over the last 30 days; the implied figure and the comparison will show when the chain is live.
Loading DRREDDY price...
DRREDDY's live option chain - put-call ratio, max pain, expected move and open-interest walls - appears during market hours (9:15-3:30 IST, Mon-Fri). Come back when the market is open for the full options view.
Companies file a balance sheet twice a year, not every quarter, so this is the most recent one published rather than the latest quarter.
Cash flow is reported for the year to date, so this covers the full period ending 2026-03-31 rather than a single quarter.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
Operating margin has gone from 17.5% to 19.1% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
2026 has paid Rs 8.00 per share, about Rs 686 on Rs 1 lakh at today's price. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.